FDA Clears New Version of AI Segmentation Software for Brain MRI
Offering rapid automated segmentation of brain structures, the ClearPoint 2.2 software reportedly enhances visualization for a variety of targeted, MRI-guided procedures.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-enabled ClearPoint 2.2 software, which provides automated segmentation of brain structures from magnetic resonance imaging (MRI) scans.
ClearPoint Neuro, the manufacturer of the software, said it provides rapid segmentation that facilitates a variety of targeted, MRI-guided procedures ranging from deep brain stimulation to laser ablation.
Here one can see a comparison of the ClearPoint Maestro Brain Model (a) and the ClearPoint 2.2 software (b), which includes segmentation of subnuclei. (Images courtesy of NeuroImage.)
The ClearPoint 2.2 software also includes the Maestro Brain Model, which was recently validated in a study published in NeuroImage. In a quantitative reproducibility analysis, researchers found the combination of the shape-constrained deformable brain model and voxel-wise tissue segmentation was superior to manual expert segmentation.
“The ClearPoint system can now offer fast, peri-procedural segmentation of the cortical structures of the brain to identify both targets and safety zones for cell and gene therapy delivery, laser ablation, biopsy and deep brain stimulation,” noted Joe Burnett, the president and CEO of ClearPoint Neuro.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
